Open Access NewsNews from the open access movement Jump to navigation |
|||
Maximizing public benefit from publicly-funded science
Carolyn Raffensperger, The Tragedy of the Anti-Commons in Science, On the Commons, March 18, 2006. Excerpt:
Few argue with the premise that the public should be the primary beneficiaries of publicly funded research and technology development. But how they should benefit is the subject of hot debate. The U.S. government’s approach has been to facilitate the transfer of technology into the market by privatizing it. The idea is that the technology will be made available to the public only if a company can have exclusive access to it and effectively protect its investment. Since the 1980’s Congress has passed numerous pieces of legislation to streamline the transfer of drugs, agricultural materials and other technologies into private hands. The most important single law is the Bayh-Dole Technology Transfer Act. This approach has resulted in what some have called the tragedy of the anti-commons – excluding people from a non-depletable commons resulting in its under-use. For instance, NIEHS and other agencies spend millions of dollars on pharmaceuticals and then transfer them to private companies who profit from the publicly funded research. Patents and licenses prevent other companies from making cheaper, more accessible versions of the drugs. By making the public pay twice, the market is actually a method for excluding the public from the very things it paid to have created.... |